This is believed to be the first large-scale analysis of gene expression signatures, tumor cell interactions and T- and B-cell interactions by digital pathology in patients treated with targeted therapy.
TORONTO (PRWEB) November 29, 2021
Biomarkers are needed to identify patients who benefit most from targeted or immune checkpoint inhibitor (ICI) therapy in metastatic melanoma. This webinar will share an analysis of biomarkers using pre-treatment melanoma samples from the dabrafenib plus trametinib arm of the randomized, Phase III COMBI-v trial using the HALO® image analysis platform combined with gene expression analysis using the Nanostring nCounter technology.
This is believed to be the first large-scale analysis of gene expression signatures, tumor cell interactions and T- and B-cell interactions by digital pathology in patients treated with targeted therapy. Distinct T-cell/B-cell signatures at baseline demonstrated prognostic value, as high T-cell/low B-cell signatures were associated with prolonged survival vs. high T-cell/high B-cell signatures. B cells may be potential biomarkers to identify patients who could achieve improved clinical benefit.
Join this webinar to learn:
- How biomarker analysis with digital pathology coupled with gene expression analysis can identify T- and B-cell signatures with prognostic value in melanoma
- How digital image analysis can identify tumor and stroma compartments and perform cell-by-cell analysis of biomarker positivity within the respective compartments to identify and quantify cellular phenotypes
- How spatial analysis can provide insight into interactions between T- and B-cells
Join Ken Schultz, Principal Scientist, Novartis, for the live webinar on Wednesday, December 15, 2021 at 1pm EST.
For more information, or to register for this event, visit Using Digital Pathology to Determine the Role of Tumor-Infiltrating B-Cells in Clinical Outcomes of Patients with Melanoma.
ABOUT INDICA LABS
Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO® and HALO AI™ for image analysis and HALO Link™ and HALO AP® to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, and toxicological pathology.
To learn more about Indica Labs, visit https://indicalab.com/
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.